NECA |
Katalog-Nr.GC15304
One-Click Copy Product Info
|
NECA (NECA) ist ein nichtselektiver Adenosinrezeptor-Agonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 35920-39-9
Sample solution is provided at 25 µL, 10mM.
NECA is a non-selective agonist of adenosine receptors [1]. NECA regulates intracellular cAMP levels by activating adenosine receptors, thereby affecting many cellular physiological processes, such as anti-inflammation, vasodilation, inhibition of neuronal activity, cardioprotection, and immune regulation [2-3].
In H9c2 cells, NECA (0.1–10μM; 20min) blocked H2O2-induced GSK-3β phosphorylation and GRP94 expression [4]. In skeletal muscle cells, NECA (100nM, 10μM; 19h) modulates CPT1B, stimulates LCAD, inhibits ACCβ mRNA gene expression [5]. In HREC cells, NECA (10μM; 24-72h) induced a time-dependent increase in cell proliferation [6].
In ex-hypoxic polycythemic mice model, NECA (0.05, 0.1µmol/kg; iv; single injection) significantly increased serum erythropoietin levels in mice with hypoxic erythrocytosis [7]. In mice that were only immunized, intranasal NECA (50μL; 1mM; intranasal administration; single administration) administration caused a significant increase in bronchoalveolar lavage total cell count (TCC), neutrophils and eosinophils [8].
References:
[1]. Knapp C M, Foye M M, Cottam N, et al. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration[J]. Pharmacology Biochemistry and Behavior, 2001, 68(4): 797-803.
[2]. Elsherbiny N M, Abd El Galil K H, Gabr M M, et al. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1[J]. European Cytokine Network, 2012, 23(3): 78-86.
[3]. Li L, Chen J, Wang Z, et al. NECA alleviates inflammatory responses in diabetic retinopathy through dendritic cell toll-like receptor signaling pathway[J]. Frontiers in Immunology, 2024, 15: 1415004.
[4]. Xing F, Han H, He Y, et al. Roles of endoplasmic reticulum stress in NECA‐induced cardioprotection against ischemia/reperfusion injury[J]. Oxidative Medicine and Cellular Longevity, 2017, 2017(1): 2490501.
[5]. Haddad M. The effect of NECA, CGS 21680, PSB 603 on fatty acid transport and oxidation in skeletal muscle cells[J]. International Journal of Pharmaceutical Sciences and Research, 2016, 7(12): 4827.
[6]. Grant M B, Davis M I, Caballero S, et al. Proliferation, migration, and ERK activation in human retinal endothelial cells through A2B adenosine receptor stimulation[J]. Investigative ophthalmology & visual science, 2001, 42(9): 2068-2073.
[7]. Nakashima J, Ohigashi T, Brookins J W, et al. Effects of 5′-N-ethylcarboxamideadenosine (NECA) on erythropoietin production[J]. Kidney international, 1993, 44(4): 734-740.
[8]. El-Hashim A Z, Abduo H T, Rachid O M, et al. Intranasal administration of NECA can induce both anti-inflammatory and pro-inflammatory effects in BALB/c mice: Evidence for A2A receptor sub-type mediation of NECA-induced anti-inflammatory effects[J]. Pulmonary Pharmacology & Therapeutics, 2009, 22(3): 243-252.
| Cell experiment [1]: | |
Cell lines | H9c2 cells |
Preparation Method | Cells were washed twice with phosphate-buffered saline (PBS) and then incubated in Tyrode solution for 2h before experiments. To examine the effect of NECA on mitochondrial membrane potential, GSK-3β phosphorylation, and GRP94, cells were exposed to 800μM H2O2 for 20 minutes to cause oxidant damage. A range concentrations of NECA (0.1–10μM) were given 10min before exposing to H2O2. In the study exploring roles of ERS and the cGMP/PKG signaling pathway in NECA-induced cardioprotection against oxidative damage, cells were exposed to 0.1μM NECA/20mM 2-DG/0.1μM KT5823 for 20min. The 2-DG and KT5823 were applied for 10min before the cells were exposed to NECA. |
Reaction Conditions | 0.1–10μM; 20min |
Applications | NECA blocked H2O2-induced GSK-3β phosphorylation and GRP94 expression. |
| Animal experiment [2]: | |
Animal models | Ex-hypoxic polycythemic mice (EHPCM) model |
Preparation Method | This in vivo experiment used the Ex-hypoxic polycythemic mice (EHPCM) model, which induced erythrocytosis by exposing mice to a low-pressure hypoxic environment for a long time. On the 3rd to 6th day after the end of the hypoxic treatment, NECA was given intravenously or intraperitoneally, and finally a short-term hypoxia stimulation was given again. The blood, kidneys and livers of the mice were then collected, and the Epo (erythropoietin) content in the serum and tissues was detected to evaluate the in vivo regulatory effect of NECA on Epo production. |
Dosage form | 0.05, 0.1µmol/kg; iv; single injection |
Applications | NECA significantly increased serum Epo levels in mice with hypoxic erythrocytosis. |
References: | |
| Cas No. | 35920-39-9 | SDF | |
| Chemical Name | (2S,3S,4R,5S)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide | ||
| Canonical SMILES | O[C@H]1[C@@H](N2C3=NC=NC(N)=C3N=C2)O[C@H](C(NCC)=O)[C@H]1O | ||
| Formula | C12H16N6O4 | M.Wt | 308.3 |
| Löslichkeit | ≥ 15.35mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2436 mL | 16.218 mL | 32.4359 mL |
| 5 mM | 648.7 μL | 3.2436 mL | 6.4872 mL |
| 10 mM | 324.4 μL | 1.6218 mL | 3.2436 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)